ABIONYX PHARMA SA (ABNX.PA) Stock Fundamental Analysis

EPA:ABNX • FR0012616852

3.43 EUR
-0.05 (-1.44%)
Last: Feb 19, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Overall ABNX gets a fundamental rating of 2 out of 10. We evaluated ABNX against 78 industry peers in the Biotechnology industry. Both the profitability and financial health of ABNX have multiple concerns. While showing a medium growth rate, ABNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ABNX has reported negative net income.
  • ABNX had a negative operating cash flow in the past year.
  • ABNX had negative earnings in each of the past 5 years.
  • In the past 5 years ABNX always reported negative operating cash flow.
ABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

  • ABNX has a Return On Assets (-35.18%) which is comparable to the rest of the industry.
  • ABNX has a Return On Equity (-83.55%) which is in line with its industry peers.
Industry RankSector Rank
ROA -35.18%
ROE -83.55%
ROIC N/A
ROA(3y)-27.55%
ROA(5y)-25.53%
ROE(3y)-53.79%
ROE(5y)-48.87%
ROIC(3y)N/A
ROIC(5y)N/A
ABNX.PA Yearly ROA, ROE, ROICABNX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • ABNX has a Gross Margin (17.78%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of ABNX has declined.
  • The Profit Margin and Operating Margin are not available for ABNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.52%
GM growth 5YN/A
ABNX.PA Yearly Profit, Operating, Gross MarginsABNX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ABNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ABNX has been increased compared to 1 year ago.
  • ABNX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ABNX has an improved debt to assets ratio.
ABNX.PA Yearly Shares OutstandingABNX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ABNX.PA Yearly Total Debt VS Total AssetsABNX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • An Altman-Z score of 9.00 indicates that ABNX is not in any danger for bankruptcy at the moment.
  • ABNX has a better Altman-Z score (9.00) than 85.90% of its industry peers.
  • A Debt/Equity ratio of 0.59 indicates that ABNX is somewhat dependend on debt financing.
  • ABNX has a Debt to Equity ratio (0.59) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Altman-Z 9
ROIC/WACCN/A
WACC8.09%
ABNX.PA Yearly LT Debt VS Equity VS FCFABNX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 1.40 indicates that ABNX should not have too much problems paying its short term obligations.
  • The Current ratio of ABNX (1.40) is worse than 61.54% of its industry peers.
  • ABNX has a Quick Ratio of 1.35. This is a normal value and indicates that ABNX is financially healthy and should not expect problems in meeting its short term obligations.
  • ABNX's Quick ratio of 1.35 is on the low side compared to the rest of the industry. ABNX is outperformed by 60.26% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.35
ABNX.PA Yearly Current Assets VS Current LiabilitesABNX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • ABNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.06%.
  • ABNX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.91%.
  • Measured over the past years, ABNX shows a very strong growth in Revenue. The Revenue has been growing by 88.92% on average per year.
EPS 1Y (TTM)-28.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.64%
Revenue 1Y (TTM)-10.91%
Revenue growth 3Y88.92%
Revenue growth 5YN/A
Sales Q2Q%-9.6%

3.2 Future

  • The Earnings Per Share is expected to decrease by -52.66% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 70.26% on average over the next years. This is a very strong growth
EPS Next Y-34.37%
EPS Next 2Y-68.63%
EPS Next 3Y-21.92%
EPS Next 5Y-52.66%
Revenue Next Year-1.09%
Revenue Next 2Y-0.54%
Revenue Next 3Y46.79%
Revenue Next 5Y70.26%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ABNX.PA Yearly Revenue VS EstimatesABNX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
ABNX.PA Yearly EPS VS EstimatesABNX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABNX. In the last year negative earnings were reported.
  • Also next year ABNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABNX.PA Price Earnings VS Forward Price EarningsABNX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABNX.PA Per share dataABNX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • A cheap valuation may be justified as ABNX's earnings are expected to decrease with -21.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.63%
EPS Next 3Y-21.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ABNX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABIONYX PHARMA SA

EPA:ABNX (2/19/2026, 7:00:00 PM)

3.43

-0.05 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-25
Earnings (Next)03-12
Inst Owners4.38%
Inst Owner ChangeN/A
Ins Owners38.37%
Ins Owner ChangeN/A
Market Cap121.80M
Revenue(TTM)4.33M
Net Income(TTM)-4.60M
Analysts85
Price Target10.71 (212.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.33%
PT rev (3m)-2.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)20.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.16
P/FCF N/A
P/OCF N/A
P/B 22.14
P/tB 2298.1
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.12
BVpS0.15
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.18%
ROE -83.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.78%
FCFM N/A
ROA(3y)-27.55%
ROA(5y)-25.53%
ROE(3y)-53.79%
ROE(5y)-48.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.52%
GM growth 5YN/A
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.4%
Cap/Sales 4.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.35
Altman-Z 9
F-Score3
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)90.3%
Cap/Depr(5y)216.62%
Cap/Sales(3y)2.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.64%
EPS Next Y-34.37%
EPS Next 2Y-68.63%
EPS Next 3Y-21.92%
EPS Next 5Y-52.66%
Revenue 1Y (TTM)-10.91%
Revenue growth 3Y88.92%
Revenue growth 5YN/A
Sales Q2Q%-9.6%
Revenue Next Year-1.09%
Revenue Next 2Y-0.54%
Revenue Next 3Y46.79%
Revenue Next 5Y70.26%
EBIT growth 1Y-41.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-86.11%
EBIT Next 3Y-29.77%
EBIT Next 5Y-63.6%
FCF growth 1Y-49.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.58%
OCF growth 3YN/A
OCF growth 5YN/A

ABIONYX PHARMA SA / ABNX.PA FAQ

What is the ChartMill fundamental rating of ABIONYX PHARMA SA (ABNX.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ABNX.PA.


What is the valuation status for ABNX stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIONYX PHARMA SA (ABNX.PA). This can be considered as Overvalued.


What is the profitability of ABNX stock?

ABIONYX PHARMA SA (ABNX.PA) has a profitability rating of 1 / 10.